Grimes, J. M., Gershkovich, A., Bogomolny, D., & Marr, B. P. (2022). Two cases of von Hippel-Lindau syndrome-associated retinal hemangioblastoma treated with belzutifan. RETINAL Cases & Brief Reports. https://doi.org/10.1097/icb.0000000000001376

Kim, S., Armand, J., Safonov, A., Zhang, M., Soni, R. K., Schwartz, G., McGuinness, J. E., Hibshoosh, H., Razavi, P., Kim, M., Chandarlapaty, S., & Yang, H. W. (2023). Sequential activation of E2F via Rb degradation and c-Myc drives resistance to CDK4/6 inhibitors in breast cancer. Cell Reports, 42(11), 113198. https://doi.org/10.1016/j.celrep.2023.113198

Schultz, K. A. P., Chintagumpala, M., Piao, J., Chen, K. S., Gartrell, R., Christison‐Lagay, E., Berry, J. L., Shah, R., & Laetsch, T. W. (2023). Children’s Oncology Group’s 2023 blueprint for research: Rare tumors. Pediatric Blood & Cancer, 70(S6). Portico. https://doi.org/10.1002/pbc.30574

Shi, C., Huang, K., Soto, J., Sankaran, R., Kalia, V., Onwumere, O., Young, M., Einbond, L., & Redenti, S. (2023). Piperlongumine inhibits proliferation and oncogenic MYCN expression in chemoresistant metastatic retinoblastoma cells directly and through extracellular vesicles. Biomedicine & Pharmacotherapy, 161, 114554. https://doi.org/10.1016/j.biopha.2023.114554